Imiquimod
| Clinical data | |
|---|---|
| Trade names | Aldara, others[1] |
| Other names | 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a698010 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Topical |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | 30 hours (topical dose), 2 hours (subcutaneous dose) |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.131.047 |
| Chemical and physical data | |
| Formula | C14H16N4 |
| Molar mass | 240.310 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Imiquimod, sold under the brand name Aldara among others, is a medication that acts as an immune response modifier that is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.[3]
Scientists at 3M's pharmaceuticals division discovered the drug and 3M obtained the first FDA approval in 1997. As of 2015, imiquimod is generic and is available worldwide under many brands. In 2021, it was the 290th most commonly prescribed medication in the United States, with more than 600,000 prescriptions.[4][5]
- ^ Cite error: The named reference
drugnameswas invoked but never defined (see the help page). - ^ "Imiquimod topical Use During Pregnancy". Drugs.com. 29 May 2019. Retrieved 14 July 2020.
- ^ "Imiquimod Topical". MedlinePlus. National Library of Medicine. Retrieved 2 June 2021.
- ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Imiquimod - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.